Posco

Postech Academy-Industry Foundation

Postech Foundation

Pohang University of Science and Technology Foundation

Ulsan National Institute of Science and Technology

Unist, Inc.

Pann-Ghill Suh

Sung-Ho Ryu

Yoe-Sik Bae

Sung Ho Ryu

Ji-Young Song

Tae-Hoon Lee

Do-Hyung Kim

Youn-Dong Kim

Taehoon Lee

Eun-Young Park

Hyun-Ju Lee

Mi-Nam Lee

Il-Shin Kim

Sang-Hoon Ha

Jong Hun Im

Young Chan Chae

Sung-Key Jang

Yu Jin Lee

Richard D Ye

Jong-young Kwak

Hyunjoo Bae

You-Suk Seo

Young-Chul Sung

Wan-Uk Kim

Hyun-Kyu Kang

Jung-Im Kim

Eun Jin Jo

Ha Young Lee

Tae Hoon Lee

Kyong-Tai Kim

Yun-Hee Kim

Yong-Soo Park

Eun-Mi Hur

SooMi Kim

Byoung Dae Lee

Jong Heon Kim

Jung-Hwan Kim

Ii Shin Kim

Youn Dong Kim

Mi-Sook Lee

Jong-Hyun Kim

Kyung-Moo Yea

Byoung-Dae Lee

Jae-Yoon Kim

This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.

Aptamer for periostin and anti-cancer composition including same

This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor. The fragment of connective tissue growth factor protein, which was found out in the present invention, is a binding region to FPRL1, effectively induces FPRL1-specific ERK phosphorylation, activates FPRL1 to increase intracellular Caconcentration, and finally, effectively induces angiogenesis, and thus, the fragment of connective tissue growth factor may be useful for a pharmaceutical composition for promoting angiogenesis, while polypeptide, antibody or a compound binding to the fragment of connective tissue growth factor protein may be useful for a pharmaceutical composition for inhibiting angiogenesis.

Pharmaceutical composition using connective-tissue growth factor

The present invention relates to a method of regulating mammalian target-of-rapamycin (mTOR) by regulating a phospholipase D (PLD) activity that generates a complex with mTOR. Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase D and raptor

The present invention relates to method of regulating mammalian target-of-rapamycin (mTOR) based on a novel finding of a regulating mechanism of mTOR by a phospholipase D (PLD), and Ras homolog enriched in brain (Rheb). Further, the present invention also relates to a method of screening inhibitors of mTOR, and a method and a composition for treating mTOR-related metabolic diseases by inhibiting mTOR.

Method of regulating mammalian target-of-rapamycin activity by interaction between phospholipase D and Rheb

Disclosed are peptides having SEQ ID NOs: 1 to 24 that induce superoxide generation by human monocytes or neutrophils; that induce an intracellular calcium increase by human peripheral blood monocytes or neutrophils; binds to formyl peptide receptor or formyl peptide receptor-like 1; that induce chemotactic migration of human monocytes or neutrophils in vitro; that induce degranulation in formyl peptide receptor expressing cells or formyl peptide receptor-like 1 expressing cells; that stimulate extracellular signal regulated protein kinase phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1; or that stimulate Akt phosphorylation via activation of formyl peptide receptor or formyl peptide receptor-like 1.

Immune-modulating peptide

The present invention relates to a method of protecting cells against damage caused at least in part by apoptosis, comprising administering to subjects a therapeutic dose of leumorphin having cytoprotective activity, and a pharmaceutical composition comprising an effective amount of leumorphin having a cytoprotective activity.

Method of protecting cells against damage and pharmaceutical composition comprising leumorphin

The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.

Peptides that antagonize FPR class receptor mediated signaling

The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release. The application also discloses methods of using the disclosed peptides.

Leukocyte stimulating peptides

Disclosed are peptides having SEQ ID NOs: 1 to 32 that can stimulate superoxide generation in human monocytes. Superoxide is the most important armory on the primary defense line of monocytes against invading pathogens, and the identification of new stimuli and the characterization of the regulatory mechanism of superoxide generation are of paramount importance.

Immune-enhancing peptides

The present application describes peptides that stimulate arachidonic acid release in target cells. The application also discloses peptides that cause intracellular calcium release.

A vaccine having a good vaccination effect, which comprises an antigen; a peptide selected from the group consisting of a peptide having the amino acid sequence of SEQ ID NO: 1, a peptide having the amino acid sequence of SEQ ID NO: 2, and a peptide derived from a peptide having the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; and an immune activator.

Vaccine composition containing a promoter peptide

Growing community of inventors

Pohang, South Korea

Pann-Ghill Suh